How does Huoxiang Zhengqi Liquid become a frequent visitor to the blacklist of quality inspection?

On the day of "3 15" counterfeiting, Jilin Huangzhenghui Pharmaceutical Co., Ltd. (hereinafter referred to as "Huangzhenghui Pharmaceutical") was notified by the US Food and Drug Administration because the production of Huoxiang Zhengqi Pills (concentrated pills) was unqualified. From June 20 17, 1 year to now, the products of Huoxiang Zhengqi have been notified as many as five times because they are unqualified. The bidding price of common drugs of Huoxiang Zhengqi is too low, and enterprises often cut corners to reduce costs in order to obtain profits. The lower punishment measures make Huoxiang Zhengqi, a commonly used medicine, a frequent visitor to the blacklist.

The unqualified Huoxiang Zhengqi Pills produced by Zhenghuanghui Pharmaceutical Company were investigated. Recently, the State Food and Drug Administration of the United States issued a notice about 10 batches of unqualified drugs. The notice showed that the batch numbers of Huoxiang Zhengqi Pills (concentrated pills) produced by Zheng Hui Pharmaceutical Co., Ltd. were 20 150403 and 20 160304, and the [test] (moisture) did not meet the relevant provisions of the seventh volume of the Ministry of Health's drug standards.

The State Food and Drug Administration of the United States requires the provincial food and drug administration where the production enterprise is located to file an investigation on the illegal acts of producing and selling unqualified drugs in accordance with relevant regulations, and disclose the results of the treatment of relevant enterprises or units that produce and sell unqualified drugs within three months. At the same time, the relevant food and drug supervision departments have asked Zhenghuanghui Pharmaceutical to suspend sales and use, recall unqualified products and carry out rectification.

According to the data, Zhenghuanghui Pharmaceutical Co., Ltd. belongs to Ji Lin Yixin Kang Technology Group Co., Ltd., and its main products are Musk Antithrombotic Pill, Dahuoluo Pill, Renshen Zaizao Pill, Huoxiang Zhengqi Pill and Teng Jian Huang Bone Pill.

This is not the first time that Huoxiang Zhengqi medicine has been blacklisted for quality inspection. On March 20 17, Jiangxi furong pharmaceutical co., ltd was informed by Fujian province that the batch number was 16030 1, because it did not meet the standard. 20 17 February, the batch number of Huoxiang Zhengqi water produced by Sichuan Hebangxudong Pharmaceutical Co., Ltd. was 150607, and the batch number of Huoxiang Zhengqi water produced by Sichuan Rainbow Pharmaceutical Co., Ltd. was notified by Sichuan American Food and Drug Administration.

2065438+February 2007, the batch number of Huoxiang Zhengqi water produced by Jilin Xinhui Pharmaceutical Co., Ltd. was 05 150409, and the batch number of Huoxiang Zhengqi water produced by Hunan Mawangdui Pharmaceutical Co., Ltd. was notified by the Food and Drug Administration of Xinjiang Uygur Autonomous Region because of the unqualified quantity and content determination. 20 17, 1 June, 2008, the batch number of Huoxiang Zhengqi Pill produced by Zheng Huang Hui Pharmaceutical Co., Ltd. was notified by the US Food and Drug Administration of Guangdong due to unqualified moisture.

The data show that Huoxiang Zhengqi is a traditional Chinese patent medicine, which is divided into pills and soft capsules. It can relieve summer-heat dampness, and is mostly used for fever, chest tightness, abdominal distension and vomiting caused by exogenous summer-heat dampness.

Commonly used low-priced drugs such as Huoxiang Zhengqi frequently appear in blacklists or enterprises cut corners to save costs. Bai Xixi, chairman of Taiji Group, once said that medical institutions only bid for drugs at low prices, and enterprises are forced to get into trouble. Low-priced drugs have no profit, and many enterprises simply do not produce them.

In 20 14, Li Zhenjiang, the chairman of Shenwei Pharmaceutical, was forced to give up Shuanghuanglian injection, which once brought the company an annual output value of 80 million yuan. At that time, Li Zhenjiang was angry and helpless about stopping production. "The highest retail price of each 20ml Shuanghuanglian injection is only 1.8 yuan, and our cost is almost twice this price." . Due to losses, Shenwei Pharmaceutical Company closed its Shuanghuanglian injection factory in Chengdu on 20 14. During this period, Li Zhenjiang also reduced the production of Banlangen granules and stopped the production of Huoxiang Zhengqi water.

Shi Lichen, founder of the third-party medical service system, said that the bidding price of commonly used drugs such as Huoxiang Zhengqi is lower, and the cost price is even higher than the price after bidding. Under the pressure of cost, enterprises often choose the latter between stopping production and cutting corners to reduce costs.

Shi Lichen said that in addition to the low bidding price, high cost pressure on enterprises, and cutting corners to reduce costs, another main reason why commonly used drugs such as Huoxiang Zhengqi are frequently blacklisted is that the regulatory authorities have lower penalties for enterprises involved. "The penalties for manufacturers with unqualified products are mostly suspension of sales, product recall and suspension of production for rectification, but these penalties will not have a great impact on enterprises. Enterprises will still choose to produce inferior drugs to earn income without serious punishment. "